Christopher P Mill, Ph.D.

Peer-Reviewed Articles

1. Fiskus, WC, Mill, CP, Issa, GC, Piel, J, Collins, M, Hentemann, M, Cuglievan, B, Hou, H, Jain, A, Malovannaya, A, Kadia, TM, Daver, N, Sasaki, K, Takahashi, K, Hammond, DE, Senapati, J, Loghavi, S, Flores, L, Su, X, DiNardo, C, Bhalla, K. Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor. Blood 147(23):2809-2820, 2026. e-Pub 2026. PMID: 41734382.
2. Birdwell, C, Fiskus, WC, Mill, CP, Kadia, TM, Daver, N, DiNardo, C, Sasaki, K, Davis, JA, Das, K, Hou, H, Jain, A, Malovannaya, A, Flores, L, Pourebrahim, R, Yuan, S, Su, X, Ceribelli, M, Bhalla, K. BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML. Leukemia 40(2):304-313, 2026. e-Pub 2026. PMID: 41419608.
3. Fiskus, WC, Mill, CP, Piel, J, Collins, M, Hentemann, M, Cuglievan, B, Birdwell, C, Das, K, Davis, JA, Hou, H, Jain, A, Malovannaya, A, Flores, L, Kadia, TM, Daver, N, Sasaki, K, Takahashi, K, Hammond, DE, Wang, J, Loghavi, S, Su, X, DiNardo, C, Delwel, R, Bhalla, K. Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML. HemaSphere 10(1), 2026. e-Pub 2026. PMID: 41551728.
4. Fiskus, WC, Mill, CP, Piel, J, Collins, M, Hentemann, M, Cuglievan, B, Birdwell, C, Das, K, Hou, H, Davis, JA, Jain, A, Malovannaya, A, Kadia, TM, Daver, N, Sasaki, K, Takahashi, K, Hammond, D, Reville, PK, Flores, L, Loghavi, S, Su, X, DiNardo, C, Bhalla, K. Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40089460.
5. Fiskus, WC, Masarova, L, Mill, CP, Birdwell, C, Das, K, Hou, H, Davis, JA, Jain, A, Malovannaya, A, Manshouri, T, Dunbar, A, Sharma, S, Kadia, TM, DiNardo, C, Bose, P, Pemmaraju, N, Loghavi, S, Su, X, Rampal, R, Törngren, M, Bhalla, K. Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase. Blood Advances 9(21):5598-5609, 2025. e-Pub 2025. PMID: 40829105.
6. DiNardo, C, Jen, WY, Montalban Bravo, G, Wang, X, Loghavi, S, Lavu, S, Short, NJ, Chien, KS, Issa, GC, Pemmaraju, N, Yilmaz, M, Andreeff, M, Borthakur, G, Kadia, TM, Daver, N, Garcia-Manero, G, Mill, CP, Su, X, Fiskus, WC, Bhalla, K. Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1. Blood Neoplasia 2(4), 2025. e-Pub 2025. PMID: 40979071.
7. Mill, CP, Fiskus, WC, DiNardo, C, Reville, PK, Davis, JA, Birdwell, C, Das, K, Hou, H, Takahashi, K, Flores, L, Ruan, X, Su, X, Loghavi, S, Khoury, J, Bhalla, K. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 38316746.
8. Fiskus W, Mill CP, Bose P, Masarova L, Pemmaraju N, Dunbar A, Birdwell C, Davis JA, Das K, Hou H, Manshouri T, Jain A, Malovannaya A, Philip K, Alhamadani N, Matthews A, Lin K, Flores L, Loghavi S, DiNardo CD, Su X, Rampal RK, Bhalla KN. Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood 145(6):612-624, 2024. e-Pub 2024. PMID: 39561280.
9. Fiskus W, Piel J, Collins M, Hentemann M, Cuglievan B, Mill CP, Birdwell CE, Das K, Davis JA, Hou H, Jain A, Malovannaya A, Kadia TM, Daver N, Sasaki K, Takahashi K, Hammond D, Reville PK, Wang J, Loghavi S, Sen R, Ruan X, Su X, Flores LB, DiNardo CD, Bhalla KN. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor. Blood 143(20):2059-2072, 2024. e-Pub 2024. PMID: 38437498.
10. Birdwell, C, Fiskus, WC, Kadia, TM, Mill, CP, Sasaki, K, Daver, N, DiNardo, C, Pemmaraju, N, Borthakur, G, Davis, JA, Das, K, Sharma, S, Horrigan, SK, Ruan, X, Su, X, Khoury, J, Kantarjian, HM, Bhalla, K. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia 38(3):545-556, 2024. e-Pub 2024. PMID: 38086946.
11. Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver N, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CD. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol 98(11):1780-1790, 2023. e-Pub 2023. PMID: 37665752.
12. Mill CP, Fiskus W, Das K, Davis JA, Birdwell CE, Kadia TM, DiNardo CD, Daver N, Takahashi K, Sasaki K, McGeehan GM, Ruan X, Su X, Loghavi S, Kantarjian H, Bhalla KN. Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. Leukemia 37(6):1336-1348, 2023. e-Pub 2023. PMID: 36977823.
13. Fiskus W, Mill CP, Birdwell C, Davis JA, Das K, Boettcher S, Kadia TM, DiNardo CD, Takahashi K, Loghavi S, Soth MJ, Heffernan T, McGeehan GM, Ruan X, Su X, Vakoc CR, Daver N, Bhalla KN. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer J 13(1):53, 2023. e-Pub 2023. PMID: 37055414.
14. Fiskus W, Daver N, Boettcher S, Mill CP, Sasaki K, Birdwell CE, Davis JA, Das K, Takahashi K, Kadia TM, DiNardo CD, Burrows F, Loghavi S, Khoury JD, Ebert BL, Bhalla KN. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia 36(11):2729-2733, 2022. e-Pub 2022. PMID: 36151141.
15. Mill CP, Fiskus W, DiNardo CD, Birdwell C, Davis JA, Kadia TM, Takahashi K, Short N, Daver N, Ohanian M, Borthakur G, Kornblau SM, Green MR, Qi Y, Su X, Khoury JD, Bhalla KN. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood 139(6):907-921, 2022. e-Pub 2022. PMID: 34601571.
16. Fiskus W, Manshouri T, Birdwell C, Mill CP, Masarova L, Bose P, Kadia TM, Daver N, DiNardo CD, Borthakur G, Khoury JD, Verstovsek S, Bhalla KN. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood Cancer J 12(1):23, 2022. e-Pub 2022. PMID: 35102145.
17. Fiskus W, Boettcher S, Daver N, Mill CP, Sasaki K, Birdwell CE, Davis JA, Takahashi K, Kadia TM, DiNardo CD, Jin Q, Qi Y, Su X, McGeehan GM, Khoury JD, Ebert BL, Bhalla KN. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J 12(1):5, 2022. e-Pub 2022. PMID: 35017466.
18. Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J 11(5):98, 2021. e-Pub 2021. PMID: 34016956.
19. Fiskus W, Mill CP, Perera D, Birdwell C, Deng Q, Yang H, Lara BH, Jain N, Burger J, Ferrajoli A, Davis JA, Saenz DT, Jin W, Coarfa C, Crews CM, Green MR, Khoury JD, Bhalla KN. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma. Leukemia 35(9):2621-2634, 2021. e-Pub 2021. PMID: 33654205.
20. Saenz DT, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury JD, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Mechanistic basis and efficacy of targeting β-catenin-TCF7L2-JMJD6-MYC axis to overcome resistance to BET inhibitors. Blood 135(15):1255-1269, 2020. e-Pub 2020. PMID: 32068780.
21. Cullum RL, Lucas LM, Senfeld JI, Piazza JT, Neel LT, Whig K, Zhai L, Harris MH, Rael CC, Taylor DC, Cook LJ, Kaufmann DP, Mill CP, Jacobi MA, Smith FT, Suto M, Bostwick R, Gupta RB, David AE, Riese Ii DJ. Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics. PLoS One 15(12):e0243901, 2020. e-Pub 2020. PMID: 33378376.
22. Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood 134(1):59-73, 2019. e-Pub 2019. PMID: 31023702.
23. Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia 33(6):1373-1386, 2019. e-Pub 2019. PMID: 30575820.
24. Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J 9(2):4, 2019. e-Pub 2019. PMID: 30647404.
25. Escudero S, Zaganjor E, Lee S, Mill CP, Morgan AM, Crawford EB, Chen J, Wales TE, Mourtada R, Luccarelli J, Bird GH, Steidl U, Engen JR, Haigis MC, Opferman JT, Walensky LD. Dynamic Regulation of Long-Chain Fatty Acid Oxidation by a Noncanonical Interaction between the MCL-1 BH3 Helix and VLCAD. Mol Cell 69(5):729-743.e7, 2018. e-Pub 2018. PMID: 29499131.
26. Sun B, Fiskus W, Qian Y, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Saenz DT, Mill CP, Nowak AJ, Jain N, Zhang L, Wang M, Khoury JD, Coarfa C, Crews CM, Bhalla KN. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Leukemia 32(2):343-352, 2018. e-Pub 2018. PMID: 28663582.
27. Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Mill CP, Sun B, Qiu P, Kadia TM, Pemmaraju N, DiNardo C, Kim MS, Nowak AJ, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. Leukemia 31(9):1951-1961, 2017. e-Pub 2017. PMID: 28042144.
28. Kabir FML, DeInnocentes P, Agarwal P, Mill CP, Riese Nd DJ, Bird RC. Estrogen receptor-α, progesterone receptor, and c-erbB/HER-family receptor mRNA detection and phenotype analysis in spontaneous canine models of breast cancer. J Vet Sci 18(2):149-158, 2017. e-Pub 2017. PMID: 27515268.
29. Saenz DT, Fiskus W, Manshouri T, Rajapakshe K, Krieger S, Sun B, Mill CP, DiNardo C, Pemmaraju N, Kadia T, Parmar S, Sharma S, Coarfa C, Qiu P, Verstovsek S, Bhalla KN. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia 31(3):678-687, 2017. e-Pub 2017. PMID: 27677740.
30. Fiskus W, Coothankandaswamy V, Chen J, Ma H, Ha K, Saenz DT, Krieger SS, Mill CP, Sun B, Huang P, Mumm JS, Melnick AM, Bhalla KN. SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents. Cancer Res 76(18):5467-78, 2016. e-Pub 2016. PMID: 27503926.
31. Kanthala S, Mill CP, Riese DJ, Jaiswal M, Jois S. Expression and purification of HER2 extracellular domain proteins in Schneider2 insect cells. Protein Expr Purif 125:26-33, 2016. e-Pub 2016. PMID: 26363121.
32. Hung JE, Mill CP, Clifton SW, Magrini V, Bhide K, Francois JA, Ransome AE, Fulton L, Thimmapuram J, Wilson RK, Kappock TJ. Draft Genome Sequence of Acetobacter aceti Strain 1023, a Vinegar Factory Isolate. Genome Announc 2(3), 2014. e-Pub 2014. PMID: 24903876.
33. Gallo RM, Bryant IN, Mill CP, Kaverman S, Riese DJ. Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant. J Cancer Res Ther Oncol 1(1):10, 2013. e-Pub 2013. PMID: 24791013.
34. Nickerson NK, Mill CP, Wu HJ, Riese DJ, Foley J. Autocrine-derived epidermal growth factor receptor ligands contribute to recruitment of tumor-associated macrophage and growth of basal breast cancer cells in vivo. Oncol Res 20(7):303-17, 2013. e-Pub 2013. PMID: 23879171.
35. Wilson KJ, Mill CP, Gallo RM, Cameron EM, VanBrocklin H, Settleman J, Riese DJ. The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist. Biochem J 443(1):133-44, 2012. e-Pub 2012. PMID: 22216880.
36. Wilson, KJ, Mill, CP, Lambert, S, Buchman, J, Wilson, TR, Hernandez-Gordillo, V, Gallo, RM, Ades, LM, Settleman, J, Riese, DJ. EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors 30(2):107-116, 2012. e-Pub 2012. PMID: 22260327.
37. Mill CP, Zordan MD, Rothenberg SM, Settleman J, Leary JF, Riese DJ. ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer. Genes Cancer 2(8):792-804, 2011. e-Pub 2011. PMID: 22393464.
38. Zordan MD, Mill CP, Riese DJ, Leary JF. A high throughput, interactive imaging, bright-field wound healing assay. Cytometry A 79(3):227-32, 2011. e-Pub 2011. PMID: 22045642.
39. Mill CP, Gettinger KL, Riese DJ. Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. Exp Cell Res 317(4):392-404, 2011. e-Pub 2011. PMID: 21110957.
40. Wilson KJ, Mill CP, Cameron EM, Hobbs SS, Hammer RP, Riese DJ. Inter-conversion of neuregulin2 full and partial agonists for ErbB4. Biochem Biophys Res Commun 364(2):351-7, 2007. e-Pub 2007. PMID: 17945187.
41. Constantine CZ, Starks CM, Mill CP, Ransome AE, Karpowicz SJ, Francois JA, Goodman RA, Kappock TJ. Biochemical and structural studies of N5-carboxyaminoimidazole ribonucleotide mutase from the acidophilic bacterium Acetobacter aceti. Biochemistry 45(27):8193-208, 2006. e-Pub 2006. PMID: 16819818.
42. Settembre EC, Chittuluru JR, Mill CP, Kappock TJ, Ealick SE. Acidophilic adaptations in the structure of Acetobacter aceti N5-carboxyaminoimidazole ribonucleotide mutase (PurE). Acta Crystallogr D Biol Crystallogr 60(Pt 10):1753-60, 2004. e-Pub 2004. PMID: 15388921.

Review Articles

1. Lucas, LM, Dwivedi, V, Senfeld, JI, Cullum, RL, Mill, CP, Piazza, JT, Bryant, IN, Cook, LJ, Miller, ST, Lott, JH, Kelley, CM, Knerr, EL, Markham, JA, Kaufmann, DP, Jacobi, MA, Shen, J, Riese, DJ. The Yin and Yang of ERBB4. Pharmacological Reviews 74(1):18-47, 2022. e-Pub 2022. PMID: 34987087.
2. Birdwell C, Fiskus W, Kadia TM, DiNardo CD, Mill CP, Bhalla KN. EVI1 dysregulation: impact on biology and therapy of myeloid malignancies. Blood Cancer J 11(3):64, 2021. e-Pub 2021. PMID: 33753715.
3. Mill CP, Chester JA, Riese DJ. EGFR may couple moderate alcohol consumption to increased breast cancer risk. Breast Cancer (Dove Med Press) 1:31-8, 2009. e-Pub 2009. PMID: 24367161.